Recent 8-K filings for APTN

• April 6, 2026, 7:59 PM ET other material materiality 0.50 positive item 8.01item 9.01

  Adaptin Bio shares approved for OTCQB quotation under ticker APTN

  Common shares approved for quotation on OTCQB Venture Market; ticker symbol APTN.

• December 23, 2025, 6:59 PM ET other material materiality 0.45 neutral item 1.01item 3.02 ◈ Equity Issuances

  Adaptin Bio raises $1M in private placement of 200,000 shares at $5.00 each

  Gross proceeds of $1.0 million from sale of 200,000 shares at $5.00 per share in a private placement.

• October 6, 2025, 7:59 PM ET other material materiality 0.35 neutral item 5.02item 8.01item 9.01

  Adaptin Bio increases CFO salary to $300k full-time; CDO salary to $150k at 50% commitment

  CFO Timothy Maness moved to full-time from 80%; base salary raised from $240k to $300k, retroactive to July 1, 2025.

• April 15, 2025, 7:59 PM ET other material materiality 0.80 negative item 2.01item 9.01 ◈ M&A Transactions

  Adaptin Bio files audited FY2024 financials; auditor warns of going concern doubt

  Net loss of $3.12M in 2024 vs $0.98M in 2023; no revenue reported.

• April 9, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Adaptin Bio completes reverse merger and $7.7M private placement for glioblastoma trial

  Reverse merger of Unite Acquisition 1 Corp. subsidiary with Adaptin; Adaptin survives and will trade on OTC Markets.

• February 18, 2025, 6:59 PM ET M&A materiality 0.90 neutral item 2.01item 3.02item 1.01item 3.03item 4.01item 5.01item 5.02item 5.03item 5.05item 5.06item 9.01 ◈ Governance Changes ×4◈ M&A Transactions ×2

  Adaptin Bio completes reverse merger with private biotech, raises ~$4.76M in private placement

  Merger between Unite Acquisition (shell) and Private Adaptin closed Feb 11, 2025; Private Adaptin becomes wholly owned subsidiary.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

2 positive 1 negative 3 neutral

source · APTN on sec.gov